医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Otsuka Europe Development and Commercialisation Ltd., a New Company for the Development of Pharmaceuticals Opens in the UK

2013年07月10日 PM04:25
このエントリーをはてなブックマークに追加


 

TOKYO & UXBRIDGE, United Kingdom

Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the formation of Otsuka Europe Development and Commercialisation Ltd. (OEDC).

Established on July 1st, 2013, OEDC is an important milestone for Otsuka’s growing European pharmaceutical business and a significant long-term investment for Otsuka in Europe. OEDC will be Otsuka’s European Research and Development Headquarters, working alongside Otsuka Pharmaceutical Europe Ltd (OPEL) to ensure the successful development and commercialisation of our products.

“We are delighted to establish this new company in the UK,” said Dean Haubrich, President and CEO of OEDC. “We believe that Otsuka has a great deal to contribute to the health and well-being of people in Europe and we look forward to reinforcing our strong, positive presence.”

OEDC and OPEL are separate entities based in the same location, just outside London. This business model allows for optimal collaboration and is a critical success factor in the evolution of our global business. Our research and development and commercial operations teams will work closely together, with aligned goals, to build one fully integrated European company which will enable us to effectively respond to the increasingly rigorous regulatory environment.

“The opening of OEDC is a very important milestone for Otsuka in Europe,” said Ole Vahlgren, President and CEO of OPEL “This significant long-term investment will strengthen Otsuka Europe’s continued efforts to bring Otsuka’s innovative medicines to patients across Europe.”

* (C)2013 IMSHealth. Calculated based on IMS World Review 2013 (Executive Summary) Reprinted with permission

     
 

About Otsuka Europe Development & Commercialisation Ltd.

 

Company Name:

Otsuka Europe Development and Commercialisation Ltd.

Date of Foundation:

1st July 2013

Capital:

€1 million

CEO & President:

Dean Haubrich

Head Office:

Hunton House, Highbridge Estate, Oxford Road, Uxbridge, Middlesex, UB8 1LX, United Kingdom

Scope of Business:

Research and Development
 

About Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: ‘Otsuka-people creating new products for better health worldwide.’ Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and for several decades has been active in research on tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.

Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The chairman Akihiko Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group has business operations in 25 countries and regions around the world, with consolidated sales of approximately USD13 billion or €10 billion for fiscal year 2012 (4/1/2012-3/31/2013). Otsuka welcomes you to visit its global website at https://www.otsuka.co.jp/en

CONTACT

Otsuka media contacts
Europe:
Otsuka
Pharmaceutical Europe Ltd.
Alison Ross, +44-(0)-1895-207122,
+44-(0)-7768-337128 (m)
aross@otsuka-europe.com
or
Japan:
Otsuka
Pharmaceutical Co., Ltd.
Jeffrey Gilbert, +81-3-6361-7379,
+81-80-8728-6039 (m)
gilbert.jeffrey@otsuka.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Herbalife Nutrition Hong Kong and Po Leung Kuk Set New World Record in Launching Healthy Active Lifestyle Mobile App
  • Median Technologies Inks a Research Collaboration Agreement for Lung Cancer Screening Programs With Xingtai People’s Hospital, Xingtai City, China
  • Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
  • Orthocell Commences Treatment of Its 1,000th Patient